ProKidney Corp.

0.75
0.02 (2.33%)
At close: Apr 22, 2025, 3:59 PM
0.74
-1.72%
After-hours: Apr 22, 2025, 07:56 PM EDT

Company Description

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.

It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.

The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.
ProKidney Corp. logo
Country United States
IPO Date Jun 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 204
CEO Dr. Bruce Culleton M.D.

Contact Details

Address:
2000 Frontis Plaza Blvd.
Winston-Salem, North Carolina
United States
Website https://www.prokidney.com

Stock Details

Ticker Symbol PROK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001850270
CUSIP Number n/a
ISIN Number KYG7S53R1049
Employer ID 98-1586514
SIC Code 2836

Key Executives

Name Position
Dr. Bruce Culleton M.D. Chief Executive Officer & Director
Carla Poulson Chief People Officer
James Coulston CPA Chief Financial Officer
Richard Williams Chief Information Officer
Todd C. Girolamo Esq., J.D., M.B.A. Chief Legal Officer & Secretary
Anu Biswas Senior Vice President of Manufacturing & Operations
Dr. Darin J. Weber Ph.D. Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
Dr. Joseph M. Stavas M.D., M.P.H. SVice President of Clinical Affairs
Dr. Ulrich Ernst Ph.D. EVice President of Science and Technology
Nikhil L. Pereira-Kamath Chief Business Officer

Latest SEC Filings

Date Type Title
Apr 21, 2025 4 Filing
Apr 18, 2025 4 Filing
Apr 16, 2025 4 Filing
Apr 14, 2025 4 Filing
Mar 31, 2025 S-4 Filing
Mar 20, 2025 S-8 Filing
Mar 17, 2025 10-K Annual Report
Mar 17, 2025 8-K Current Report
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing